SCHEMBL4148781

SCHEMBL4148781

O=C(N[C@H]1CCCN(c2ccccc2)C1)C12CC3CC(C1)C(O)C(C3)C2

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.48
ALDH1A1 P00352 2/20 0.43
LMNA P02545 1/20 0.43
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
MAPK1 P28482 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
EPHX1 P07099 2/20 0.39
USP2 O75604 1/20 0.39
HSD11B1 P28845 2/20 0.38
DRD2 P14416 1/20 0.38
DRD3 P35462 1/20 0.38
MAPT P10636 1/20 0.38
P2RX7 Q99572 1/20 0.38
NOTUM Q6P988 1/20 0.37
USP30 Q70CQ3 1/20 0.37
PPARD Q03181 1/20 0.37
PPARA Q07869 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4142873 0.91 CNR1 (0.54) CNR1ALDH1A1LMNARAB9AKMT2A
SCHEMBL5950362 0.90 CNR1 (0.38) CNR1ALDH1A1RAB9AKMT2AEPHX1
SCHEMBL4005560 0.90 CNR1 (0.38) CNR1ALDH1A1RAB9AKMT2AEPHX1
SCHEMBL27707859 0.90 CNR1 (0.38) CNR1ALDH1A1RAB9AKMT2AEPHX1
SCHEMBL4010313 0.89 CNR1 (0.47) CNR1ALDH1A1LMNARAB9AKMT2A
SCHEMBL4795963 0.88 ALDH1A1 (0.48) CNR1ALDH1A1LMNARAB9AKMT2A
SCHEMBL4154534 0.87 EPHX2 (0.44) CNR1RAB9AKMT2ASMN1; SMN2
SCHEMBL4138523 0.87 HPGD (0.42) CNR1ALDH1A1RAB9AKMT2ASMN1; SMN2
SCHEMBL4140568 0.87 EPHX1 (0.43) KMT2AEPHX1HSD11B1NOTUM
SCHEMBL4138527 0.86 CNR1 (0.37) CNR1RAB9AKMT2AMAPK1EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US claimed
EP-1778229-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2009-06-17 EP disclosed
EP-1778229-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-05-02 EP disclosed
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US disclosed
WO-2006020598-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122197-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 CNR1 516/4885ALDH1A1 311/4885LMNA 2149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.